Cardax patents protect compositions of matter, pharmaceutical compositions, and pharmaceutical uses of its astaxanthin and related products in certain disease areas.

The Cardax patent portfolio consists of 21 issued patents, including 14 in the U.S. and seven in China, India, Japan, and Hong Kong. These patents will expire between 2023 and 2028, subject to patent extensions. Cardax five patent applications pending in Europe, Canada, and Brazil.